The Times Australia
Google AI
PR Newswire

.

The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start

The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start

ZÜRICH, Nov. 9, 2020 /PRNewswire/ -- Concept Medical Inc.,[1] focused on vascular intervention drug delivery devices, has announced the enrolment of the first patient in the SirPAD (Sirolimus in Peripheral Artery Disease) trial.

The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start The study is initiated by Prof. Dr. med Nils Kucher (also the Principal Investigator) in charge of the Clinic of Angiology at the University Hospital Zurich, Switzerland.

SirPAD[2] is the first All-Comer randomized controlled clinical trial (RCT) investigating major adverse limb events in PAD patients with lesions below the inguinal ligament.

SirPAD[3] is investigator-initiated, single-center, randomized, non-inferiority, open-label clinical trial investigating whether the use of MagicTouch PTA[4] sirolimus-coated balloon catheters in patients with peripheral artery disease of the femoro-popliteal or below-the-knee segment is not inferior to that of uncoated balloon catheters for major clinical outcomes (unplanned major amputation, target limb re-vascularization). Total of 1200 patients are to be randomized 1:1 (600 patients per treatment group).

The primary objective is to evaluate whether the use of sirolimus-coated balloon catheters (MagicTouch PTA[5]) is non-inferior to uncoated balloon catheters in infra-inguinal angioplasty to prevent one-year major adverse limb events (MALE), including unplanned major amputation of the target limb and target lesion re-vascularization for critical limb ischemia, in a representative population of patients with PAD (`all-comers`). If the criterion for non-inferiority is confirmed, the study will test whether sirolimus-coated catheters (MagicTouch PTA[6]) are superior to uncoated catheters for important secondary outcomes and for the primary outcome itself according to pre-specified criteria for hierarchical analysis.

The index patient was successfully enrolled on 3rdNovember 2020 in University Hospital Zurich.

The study is initiated by Prof. Dr. med Nils Kucher (also the Principal Investigator) in charge of the Clinic of Angiology at the University Hospital Zurich, Switzerland.

Prof. Dr. med Nils Kucher was excited to initiate the study and said, "Over the past decade, a few RCTs have compared the efficacy and safety of drug-coated (mainly paclitaxel-coated) devices vs. that of uncoated ones, and demonstrated a significant reduction in restenosis rates, late lumen loss, and incidence of target lesion re-vascularization. However, the size of these trials was often too small to draw firm conclusions concerning major clinical outcomes. Moreover, substantial heterogeneity of the study populations and too restrictive eligibility criteria limited their external validity, leading to a difficult interpretation of the results of meta-analyses. Indeed, these trials adopted surrogate (and rather subjective) outcomes as the primary outcome, such as vessel patency and target limb re-vascularization, which may be difficult to objectively judge in the setting of an open-label trial, rather than ´hard´ objective clinical endpoints, such as major amputation or urgent revascularization due to critical limb ischemia. The aim of the SirPAD trial is to compare the efficacy, as defined by a composite of clinically relevant non-subjective 'hard' outcomes (major amputation and target lesion re-vascularization for critical limb ischemia), of sirolimus-coated vs. uncoated balloon angioplasty for peripheral artery disease in patients."

www.conceptmedical.com[7]

Photo:https://mma.prnasia.com/media2/1329810/enrolment_of_the_first_patient_in_the_sirpad.jpg?p=medium600[8]

Logo: https://mma.prnasia.com/media2/1244676/Concept_Medical_Logo.jpg?p=medium600[9]

Source: Concept Medical Inc.

References

  1. ^ Concept Medical Inc., (www.conceptmedical.com)
  2. ^ SirPAD (www.conceptmedical.com)
  3. ^ SirPAD (www.conceptmedical.com)
  4. ^ MagicTouch PTA (www.conceptmedical.com)
  5. ^ MagicTouch PTA (www.conceptmedical.com)
  6. ^ MagicTouch PTA (www.conceptmedical.com)
  7. ^ www.conceptmedical.com (www.conceptmedical.com)
  8. ^ https://mma.prnasia.com/media2/1329810/enrolment_of_the_first_patient_in_the_sirpad.jpg?p=medium600 (mma.prnasia.com)
  9. ^ https://mma.prnasia.com/media2/1244676/Concept_Medical_Logo.jpg?p=medium600 (mma.prnasia.com)

Read more https://www.prnasia.com/story/archive/3184609_AE84609_0

Business Times

Mint Payments partners with Zip Co to add flexible payment option…

Mint Payments, Australia's leading travel payments specialist, today announced a partnership with Zip Co (ASX: ZIP), a digi...

When Holiday Small Talk Hurts Inclusion at Work

Dr. Tatiana Andreeva, Associate Professor in Management and Organisational Behaviour, Maynooth University, Ireland, tatia...

Reflections invests almost $1 million in Tumut River park to boos…

Reflections Holidays, the largest adventure holiday park group in New South Wales, has launched four tiny homes at its Tu...

The Times Features

Why Fitstop Is the Gym Australians Are Turning to This Christmas

And How ‘Training with Purpose’ Is Replacing the Festive Fitness Guilt Cycle As the festive season ...

Statement from Mayor of Randwick Dylan Parker on Bondi Beach Terror Attack

Our community is heartbroken by the heinous terrorist attack at neighbouring Bondi Beach last nigh...

Coping With Loneliness, Disconnect and Conflict Over the Christmas and Holiday Season

For many people, Christmas is a time of joy and family get-togethers, but for others, it’s a tim...

No control, no regulation. Why private specialist fees can leave patients with huge medical bills

Seeing a private specialist increasingly comes with massive gap payments. On average, out-of-poc...

Surviving “the wet”: how local tourism and accommodation businesses can sustain cash flow in the off-season

Across northern Australia and many coastal regions, “the wet” is not just a weather pattern — it...

“Go west!” Is housing affordable for a single-income family — and where should they look?

For decades, “Go west!” has been shorthand advice for Australians priced out of Sydney and Melbo...

Housing in Canberra: is affordable housing now just a dream?

Canberra was once seen as an outlier in Australia’s housing story — a planned city with steady e...

What effect do residential short-term rentals have on lifestyle and the housing market in Brisbane?

Walk through inner-Brisbane suburbs like Fortitude Valley, New Farm, West End or Teneriffe and i...

The Sydney Harbour Bridge faces tolls once again — despite tolls being abolished years ago. Why?

For many Sydney motorists, the Harbour Bridge toll was meant to be history. The toll booths cam...